Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Clinical trial NCT00043706 · COMPLETED
Trial details
- NCT number
- NCT00043706
- Sponsor
- Genzyme, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.